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Abstract
Background: Genomic DNA methylation affects approximately 1% of DNA bases in humans, with
the most common event being the addition of a methyl group to the cytosine residue present in
the CpG (cytosine-guanine) dinucleotide. Methylation is of particular interest because of its role in
gene silencing in many pathological conditions. CpG methylation can be measured using a wide
range of techniques, including methylation-specific (MS) PCR, pyrosequencing (PSQ), bisulfite
sequencing (BS) and methylation-sensitive restriction enzyme (MSRE) PCR. However, although it
is possible to utilise these methods to measure CpG methylation, optimisation of the assays can be
complicated due to the absence of suitable control DNA samples.
Results:  To address this problem, we have developed an approach that employs multiple
displacement based whole genome amplification (WGA) with or without SssI-methylase treatment
to generate CpG methylated and CpG unmethylated DNA, respectively, that come from the same
source DNA.
Conclusion: Using these alternately methylated DNA samples, we have been able to develop and
optimise reliable MS-PCR, PSQ, BS and MRSE-PCR assays for CpG methylation detection, which
would otherwise not have been possible, or at least have been significantly more difficult.
Background
The major epigenetic alterations in eukaryotes are DNA
methylation and histone acetylation. Promoter methyla-
tion has an important role in controlling the binding of
transcription factors and other proteins to the DNA,
which in turn modulate the association of methyl-DNA-
binding proteins and histone deacetylases to the tran-
scription start sites. This modulation is critical in regulat-
ing the switch between transcriptionally active
euchromatin (unmethylated) and transcriptionally silent
heterochromatin (methylated) and in turn gene expres-
sion [1,2]. The most common methylation event is the
addition of a methyl group to the cytosine present in the
CpG (cytosine-guanine) dinucleotide [3]. These dinucle-
otides exist as either CpG islands or as sparsely distributed
CpG motifs within the promoter regions of many genes.
Hypermethylation (methylation) of these islands or
motifs results in transcriptional silencing [4], whilst
hypomethylation (demethylation), either global or gene
specific, induces expression [5].
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PCR-based techniques can be used to investigate the
methylation status of CpG islands or motifs with the
available methods being categorised based on the require-
ment for bisulfite treatment prior to PCR (or sequencing).
Bisulfite treatment converts all unmethylated cytosine to
uracil/thymine, while methylated cytosines are retained.
MS-PCR, PSQ or BS can then be used to measure cytosine
conversion or retention and thus distinguish methylated
from unmethylated residues [6,7]. As an alternative to
bisulfite-based approaches, methylation-sensitive restric-
tion endonucleases, which contain one or more CpG
motifs within their recognition site, can be employed
[8,9]. These enzymes will only cut the DNA if the cytosine
within the CpG motif is unmethylated. For this assay, the
DNA (non bisulfite treated) is first digested and then sub-
jected to amplification by PCR (MSRE-PCR) using primers
flanking the site of interest. If the CpG is methylated, then
a PCR product will be generated, however, if there is no
methylation, no product will be generated as the site will
have been cut.
When designing methylation detection assays using MS-
PCR, BS, PSQ or MSRE-PCR optimisation of the amplifi-
cation conditions, including primer design, magnesium
chloride concentration and annealing temperature, is
essential to ensure correct interpretation of results. To ena-
ble this, suitable control DNA samples are required that
correspond to fully CpG unmethylated and fully CpG
methylated DNA.
In this paper, we describe an adaptation of the approach
described by Weisenberger and colleagues [10]. The meth-
ods presented here use a combination of whole genome
amplification (WGA) using the multiple displacement
amplification (MDA) approach [11] with or without sub-
sequent treatment with the CpG methylating enzyme SssI-
methylase (M.SssI) to generate matched DNA samples dif-
fering in only their CpG methylation. The DNA samples
generated using this method can be used as CpG methyl-
ation control samples for optimising PCR-based assays, as
well as internal controls for all of the steps involved in a
methylation detection experiment.
Results and Discussion
Alterations in DNA methylation status can modulate gene
expression in the absence of DNA base changes. Although
several PCR-based approaches can be implemented to
measure methylation, before these can be reliably used to
study patient samples it is first essential to optimise assay
conditions. Furthermore, as PCR amplification is often
the end point measurement in methylation analysis, it is
important to have amplification controls as a way of mon-
itoring the whole experimental process, to ensure each
step and treatment has worked optimally. While commer-
cially available universally methylated and unmethylated
DNA can be used as controls, these have not always been
reliable in our assays. As a consequence, we have devel-
oped a procedure for generating CpG methylated and
CpG unmethylated DNA from the same source DNA
using MDA and M.SssI treatment.
MDA is a rolling circle amplification method, originally
developed for the amplification of large circular DNA
templates [12], which has been adapted for the amplifica-
tion of the entire genome [13,14]. This amplification
method can generate DNA strands in excess of 10 kb in
length, without prior knowledge of the target template
[15]. In the context of this work, MDA generates amplified
DNA free of any methylation due to the absence of meth-
ylase activity for the MDA enzyme (phi29 polymerase). As
a consequence the DNA generated my MDA will be
unmethylated DNA (uDNA). SssI  methylase has been
reported to methylate the fifth position of cytosine in all
CpG dinucleotides [16], thus the treatment of MDA gen-
erated DNA with M.SssI  will generate CpG methylated
DNA (mDNA). A flow diagram of the steps involved is
displayed in Figure 1.
The use of bisulfite treated mDNA and uDNA as template
for MS-PCR has allowed for the optimisation of several
primer sets. Primers for MS-PCR will ideally only generate
a product with either mDNA or uDNA, but not both. Typ-
Flow diagram demonstrating the steps involved in generation  of differentially methylated DNA and the downstream appli- cations of the DNA Figure 1
Flow diagram demonstrating the steps involved in generation 
of differentially methylated DNA and the downstream appli-
cations of the DNA.BMC Molecular Biology 2007, 8:91 http://www.biomedcentral.com/1471-2199/8/91
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ical results obtained are displayed in Figure 2a. Using
MMP-2 and BRCA-1 as examples, the primers that were
designed to amplify methylated DNA only amplified
mDNA and not uDNA. Conversely those primers that
were designed to amplify unmethylated DNA only ampli-
fied uDNA and not mDNA. None of the MS-PCR primers
sets amplified untreated genomic DNA; in addition wild-
type primers did not amplify the bisulfite treated mDNA
or uDNA (Figure 2a). When the primers were applied to
bisulfite treated DNA from the HFFF2, MDA-MB231 and
MDA-MB468 cell lines, all three were demonstrated to be
unmethylated for BRCA-1 (Figure 2b). The analysis of
MMP-2 methylation status indicated that both MDA-
MB231 and MDA-MB468 were methylated, whilst HFFF2
was unmethylated (Figure 2b).
The regions interrogated by MS-PCR for BRCA-1 were also
studied by pyrosequencing (PSQ). PSQ, as first described
by Ronaghi et al [17,18], is a DNA sequencing approach
that utilizes a combination of four enzymes (DNA
polymerase, ATP sulfurylase, luciferase and apyrase) to
perform DNA synthesis in real time (for a review of this
technology see [19]). As applied to methylation detection,
PSQ can quantify multiple CpG sites per amplicon,
whereby the percentage of C bases (methylated) versus T
bases (unmethylated) can be calculated for each CpG
position in each sample. In order to analyze the BRCA-1
amplicon, studied by MS-PCR, two sets of PCR and
sequencing primers (Table 1) were required. The results
for uDNA and mDNA demonstrate differential CpG
methylation and are in agreement with the MS-PCR
results, whereby mDNA is methylated and uDNA is
unmethylated. For the eight CpG motifs studied in the
uDNA all had undergone 100% bisulfite conversion from
C to T, confirming the fully unmethylated status of this
DNA as well as indicating that the bisulfite conversion
step is working optimally. Similarly, for the eight CpG
motifs studied in the mDNA, all of the eight CpG sites
showed methylation (C bases retained), with an average
of only 25% conversion, indicated by a 75% (non-con-
verted) to 25% (converted) ratio (average over the eight
sites) of C to T bases. Thus the M.SssI treatment step is
75% efficient at methylating CpG motifs. These findings
suggest that although the MDA and M.SssI  treatment
enriches the proportion of methylated DNA, up to 25% of
the DNA, within a single sample, may not be methylated
at any one of these CpG motifs. Despite this, the results
for uDNA and mDNA can be clearly and reproducibly dis-
tinguished by PSQ.
When genomic DNA and bisulfite-treated mDNA and
uDNA were used as template for sequencing in combina-
tion with primers for MMP-14, a PCR product was gener-
ated for all samples (Figure 3a). BS primers were designed
so that they were capable of amplifying the region of inter-
est from all samples, irrespective of methylation status.
This was made possible by ensuring that the primers did
not contain potential CpG sites that may be prone to
methylation. When these PCR products were sequenced,
comparison of the results from genomic DNA, mDNA
and uDNA allowed discrimination between cytosines that
had been methylated (protected from bisulfite conversion
and thus remaining as cytosines) or unmethylated
(unprotected and converted to thymine) (Figure 3b–d).
These bases are indicated in Figure 3b–d by asterix (*). In
untreated genomic DNA (Figure 3b) all cytosines are
retained, however, in the MDA-generated uDNA (Figure
3c), following bisulfite treatment, all cytosines are con-
verted to thymine. Whilst for the M.SssI treated sample,
mDNA (Figure 3d), only those cytosines in CpG dinucle-
otides remain unchanged indicating that they are methyl-
ated.
Methylation Specific PCR results for MMP-2 and BRCA-1 Figure 2
Methylation Specific PCR results for MMP-2 and 
BRCA-1. Two sets of primers were designed for both MMP-
2 and BRCA-1, one set that would amplify only methylated 
DNA and a second set that would amplify only unmethylated 
DNA. a) Those primers that were designed to amplify meth-
ylated DNA only amplified mDNA and not uDNA or 
genomic DNA, whilst those primers designed to amplify 
unmethylated DNA only amplified uDNA and not mDNA or 
genomic DNA. Furthermore wild type primers were unable 
to amplify either uDNA or mDNA, but could amplify 
genomic DNA. b) When used in conjunction with cell line 
DNA they detected that the MMP-2 promoter is methylated 
for MDA-MB231 (231) and MDA-MB468 (468), but not 
HFFF2. However, the promoters for MDA-MB231 (231), 
MDA-MB468 (468) and HFFF2 were all identified as being 
unmethylated for BRCA-1.BMC Molecular Biology 2007, 8:91 http://www.biomedcentral.com/1471-2199/8/91
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The results of the MSRE-PCR using mDNA and uDNA are
shown in Figure 4a. The promoter regions of both MMP-
1 and MMP-3 have a low proportion of CpG dinucle-
otides. Associated with some of these motifs are recogni-
tion sites for restriction enzymes that are sensitive to CpG
methylation (e.g. HpyCH4IV, HpaII, SsiI), whereby when
present methylation blocks the enzymes from cutting.
Digestion of uDNA with HpyCH4IV resulted in cutting of
DNA at unmethylated CpG motifs, however, mDNA that
possesses methylated CpG motifs remained intact. Subse-
quent PCR, using primers spanning the restriction site,
gave a PCR product with mDNA, indicating CpG methyl-
ation and protection, but not with uDNA, showing
absence of CpG methylation and sensitivity to digestion.
When HFFF2, MDA-MB231 and MDA-MB468 cell line
DNAs were subjected to HpyCH4IV digestion and MMP-1
and MMP-3 PCR the results demonstrated that the CpG
site in the MMP-1 amplicon was methylated in HFFF2 and
MDA-MB468, but unmethylated in MDA-MB231 (Figure
4b). The observations for MMP-3 indicated that the CpG
site is methylated in all three cell lines (Figure 4b) as all
gave a PCR product. Digestion negative samples gave PCR
products for all DNA samples (Figure 4a and 4b), proving
that the MSRE-PCR results were specific for detection of
methylation status and not a failure in the amplification
reaction.
Conclusion
The results demonstrate that the combination of MDA
and M.SssI treatment generate DNAs that differ only in
their CpG methylation status. The examples described
herein illustrate uDNA and mDNA can act as methyla-
tion-status specific controls for both assay optimisation
and as internal controls for methylation experiments. This
is important for several reasons; (i) it enables primer and
reaction optimisation, (ii) it allows for an experimental
checkpoint, for instance ensuring bisulfite conversion is
complete, as PCR products will be generated from mDNA
and uDNA with both sets of methylation status detection
primers if the conversion is incomplete, or for MSRE-PCR
to ensure complete digestion and (iii) if mDNA and
uDNA controls are processed along side test samples
when the controls give expected results then the results
obtained from the test samples should be more reliable.
Methods
DNA extraction
Genomic DNA was extracted using the Qiagen DNA Mini-
kit (Qiagen, Crawley, UK) from normal breast tissue
obtained following breast reduction surgery, following
ethics approval from the North East London LREC. DNA
was also obtained from the cell lines HFFF2, MDA-MB231
and MDA-MB468, using the same technique. DNA con-
centration was determined using the Nano-drop spectro-
photometer (NanoDrop Technologies, Wilmington,
Table 1: Primer sequences for MS-PCR, PSQ, BS and MSRE-PCR
Gene Primer Sequence (5' – 3') Technique Methylated (m) /
Unmethylated (u)
Reference Base pair 
location
BRCA-1 F GGTTAATTTAGAGTTTCGAGAGACG MS-PCR m Genbank: 
NT_010755.15
5001854 – 5001830
R TCAACGAACTCACGCCGCGCAATCG m 5001697 – 5001673
F GGTTAATTTAGAGTTTTGAGAGATG u 5001854 – 5001830
R TCAACAAACTCACACCACACAATCA u 5001697 – 5001673
MMP-2 F GGACGTTAAGGGTTTAGAGC MS-PCR m Genbank: 
NT_010498.15
9127002 – 9127021
R CAATACACGACCTCGTCAC m 9127086 – 9127104
F GGATGTTAAGGGTTTAGAGT u 9127002 – 9127021
R CAATACACAACCTCATCAC u 9127086 – 9127104
BRCA-1-PSQ- PCRa F TAGGGGGTAGATTGGGTGGTTA PSQ Genbank: 
NT_010755.15
5001871 – 5001850
R CCCCCTCCAAAAAATCTCA 5001675 – 5001656
BRCA-1-PSQ-Sa TGGGTGGTTAATTTAGAGT 5001859 – 5001841
BRCA-1-PSQ-PCRb F TGAGAGTAGGGGTTTAGTTATTTGAGAA PSQ 5001614 – 5001641
R TTTCTATCCCTCCCATCCTCTAATTAT 5001795 – 5001821
BRCA-1-PSQ-Sb TTTGTTTTTAGTTTAGGAAG 5001651 – 5001670
MMP-14 F TTGTAATTGGATTTAGGTTAAAA BS Genbank: 
NT_026437.11
4305511 – 4305533
R AACACTAAACTTAAATTCCTAAACC 4305741 – 4305765
MMP-1 F CCAGGCCTCAGTGGAGCTA MSRE-PCR Genbank: 
NT_033899.7
6233232 – 6233214
R AATGGGAAGACATTCTCACGA 6233000 – 6232982
MMP-3 F CAACTTCAAAGCATCTGCTAATT MSRE-PCR Genbank: 
NT_033899.7
6277588 – 6277566
R ATGGGCAGAATAGAACAAAGAGG 6277355 – 6277333BMC Molecular Biology 2007, 8:91 http://www.biomedcentral.com/1471-2199/8/91
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USA). Both procedures were performed following manu-
facturer's instructions.
Primer design
The process of primer design for MS-PCR and BS is critical
when using these techniques and it is highly recom-
mended to use specialised software as standard
approaches and programs will not be sufficient. For this
study, we used either Methyl Primer Express version 1.0
(Applied Biosystems, Foster City, USA) for primer design
(MMP-2 and MMP-14) or utilised primers reported previ-
ously [BRCA-1 [20]]. Primer design for pyrosequencing
was performed using the PSQ assay design software ver-
sion 1.0.6 (Biotage, Uppsala, Sweden), whilst primer
design for MSRE-PCR can be performed using standard
primer design programs. All primers were obtained from
Sigma-Aldrich (Gillingham, UK)
Whole Genome Amplification
DNA was amplified using the GenomiPhi Amplification
Kit (Amersham Biosciences, Little Chalfont, UK) accord-
ing to manufacturer's instructions. Briefly, amplification
was carried out in two individual steps. The step 1 reaction
mixture contained 5–10 ng of DNA in 1 μl of sterile water
and 9 μl of Sample Buffer. This mixture was heated at
95°C for 3 minutes and then chilled on ice. Step 1 results
in denaturation of the genomic DNA template. The step 2
reaction (amplification) mixture contained 9 μl of Reac-
tion Buffer, 1 μl of Enzyme Mix and the 10 μl from Step 1.
Methylation-Sensitive Restriction Enzyme PCR for MMP-1  and MMP-3 Figure 4
Methylation-Sensitive Restriction Enzyme PCR for 
MMP-1 and MMP-3. a) PCR using primers spanning the 
restriction site for MMP-1 and MMP-3 gave a PCR product 
with mDNA but not with uDNA. In contrast, undigested 
samples gave PCR products for both mDNA and uDNA. b) 
PCR using digested DNA from MDA-MB231 (231), MDA-
MB468 (468) and HFFF2 identified that the CpG motif is 
methylated for all three cell lines in the MMP-3 amplicon, but 
only for MDA-MB468 (468) and HFFF2 for the MMP-1 ampli-
con, with the MDA-MB231 (231) being unmethylated. How-
ever, the undigested DNA gave a PCR product with all three 
cells lines.
Bisulfite sequencing results for MMP-14 Figure 3
Bisulfite sequencing results for MMP-14. a) When 
genomic DNA (lane 1) and bisulfite treated mDNA (lane 2) 
and uDNA (lane 3) were used as template for sequencing in 
combination with primers for MMP-14 a PCR product was 
generated for all samples but not the negative control (lane 
4). Sequencing results for b) non-amplified genomic DNA, c) 
uDNA and d) mDNA demonstrate that MDA treatment gen-
erates DNA (uDNA) free of all methylation as when it is 
bisulfite treated all cytosine are converted to thymine [indi-
cated by asterix (*)]. In addition, sequencing also demon-
strates that M.SssI treatment (mDNA) methylates CpG 
motifs as cytosines are retained when present as part of a 
CpG dinucleotide (indicated by *).BMC Molecular Biology 2007, 8:91 http://www.biomedcentral.com/1471-2199/8/91
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The amplification reaction was incubated at 30°C for 16–
18 hours. Step 2 allows for binding of the exonuclease
resistant random hexamers and subsequent isothermal
amplification. The enzyme was inactivated by heating at
65°C for 10 minutes, followed by cooling to 4°C.
Assessment of amplification and purification
Five microlitres of each amplification reaction was electro-
phoresed through a 1% agarose gel and stained with
ethidium bromide in order to assess product yield and
product length. Amplification products were purified
using the QIAquick PCR Purification Kit (Qiagen) and
DNA concentration was determined using a Nano-drop
spectrophotometer.
CpG methylation
CpG motifs within the WGA DNA were methylated using
the CpG Methylase, M.SssI  (New England Biolabs,
Hitchin, UK) according to manufacturer's instructions.
Briefly, 1.5 μg of WGA DNA was combined with 2 μl of
10x NEBuffer 2, 0.1 μl of S-adenosylmethionine (SAM), 5
units of M.SssI and sterile water up to a final volume of 20
μl. The reaction was incubated at 37°C for 1 hour, before
being purified using the QIAquick PCR Purification Kit
and the DNA concentration determined using a Nano-
drop spectrophotometer.
Bisulfite treatment
DNA was bisulfite treated using the EpiTect Bisulfite Kit
(Qiagen) according to manufacturer's instructions.
Briefly, 1 μg of either CpG methylated WGA DNA,
unmethylated WGA DNA or cell line DNA in 20 μl of
water was combined with 85 μl of Bisulfite mix and 35 μl
of DNA protect buffer. The bisulfite DNA conversion was
performed using the following conditions; denaturation 5
min 99°C, incubation 25 min 60°C, denaturation 5 min
99°C, incubation 85 min 60°C, denaturation 5 min
99°C, incubation 175 min 60°C, hold 20°C. The bisulfite
converted DNA was purified following manufacturer's
instructions. Briefly, the bisulfite reaction was mixed with
560 μl of Buffer BL, applied to the spin column and cen-
trifuged at 12,000 rpm for 1 min. The flow through was
discarded and the column washed with 500 μl of Buffer
BW. Buffer BD (500 μl) was applied to the column and
incubated at room temperature for 15 min. The column
was centrifuged to remove Buffer BD and then washed
twice with Buffer BW (500 μl). Residual BW buffer was
removed by an additional spin (12,000 rpm, 1 min).
Buffer EB (20 μl) was added to the column to elute the
DNA. The DNA concentration was determined using a
Nano-drop spectrophotometer.
Methylation-specific PCR
PCR was carried out in a 25 μl volume containing 25 ng
of either CpG methylated and bisulfite treated WGA DNA
(fully methylated), bisulfite treated WGA DNA (fully
unmethylated) or cell line DNA, 1 μl of each primer
(Table 1) (2 mM stock) for either BRCA-1 (methylated or
unmethylated) or MMP-2 (methylated or unmethylated),
2 μl of 2.5 mM dNTP mix (Invitrogen, Carlsbad, USA), 2.5
μl of 10x PCR buffer, 1.25 μl of 50 mM MgCl2, 0.1 μl of
Platinum Taq DNA polymerase (5 U/μl) (Invitrogen) and
sterile H2O up to a final volume of 25 μl.
Amplification was performed using a "Touchdown PCR"
approach, conditions were as follows: initial denaturation
for 2 min at 95°C; 20 cycles of denaturing for 30 sec at
94°C, annealing for 30 sec starting at 65°C and decreas-
ing by 0.5°C/cycle and elongation for 30 sec at 72°C; fol-
lowed by 15 cycles of denaturing for 30 sec at 94°C,
annealing for 30 sec at 55°C and elongation for 30 sec at
72°C; then 10 min at 72°C. Five microlitres of each
amplification reaction was electrophoresed through a 1%
agarose gel and stained with ethidium bromide in order to
analyse results.
Pyrosequencing
PCR was carried out in a 25 μl volume containing 25 ng
of either CpG methylated and bisulfite treated WGA DNA
(fully methylated) or  bisulfite treated WGA DNA (fully
unmethylated) or cell line DNA, 1 μl of each primer (PSQ-
PCR; Table 1) (2 mM stock) for BRCA-1, 2 μl of 2.5 mM
dNTP mix (Invitrogen), 2.5 μl of 10x PCR buffer, 2.5 μl of
50 mM MgCl2, 0.1 μl of Platinum Taq DNA polymerase (5
U/μl) (Invitrogen) and sterile H2O up to a final volume of
25 μl.
Amplification was performed using the following condi-
tions: initial denaturation for 2 min at 95°C; 45 cycles of
denaturing for 30 sec at 94°C, annealing for 30 sec at
58°C and elongation for 30 sec at 72°C; then 10 min at
72°C. Five microlitres of each amplification reaction was
electrophoresed through a 1% agarose gel and stained
with ethidium bromide in order to analyse results. Using
the PCR products as template, PSQ reactions were per-
formed using the BRCA-1 PSQ-S primers (Table 1) and
the SQA reagent kit (Biotage, Uppsala, Sweden), follow-
ing manufacturer's instructions. The results were analyzed
using a Biotage PSQ 96MA pyrosequencing system with
dedicated Pyro Q-CpG software (Biotage).
Bisulfite sequencing
PCR was carried out in a 25 μl volume containing 25 ng
of either CpG methylated and bisulfite treated WGA DNA
(fully methylated), bisulfite treated WGA DNA (fully
unmethylated) or non-amplified and untreated genomic
DNA, 1 μl of each primer (Table 1) (2 mM stock) for
MMP-14, 2 μl of 2.5 mM dNTP mix (Invitrogen), 2.5 μl of
10x PCR buffer, 1.25 μl of 50 mM MgCl2, 0.1 μl of Plati-Publish with BioMed Central    and   every 
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num Taq DNA polymerase (5 U/μl) (Invitrogen) and ster-
ile H2O up to a final volume of 25 μl.
Amplification was performed as described above with the
PCR products being purified using the QIAquick PCR
Purification Kit. Using the PCR products as template, cycle
sequencing reactions were performed using the MMP-14
Forward and reverse primers and the BigDye Terminator
Version 3.1 Kit (Applied Biosystems) following manufac-
turer's instructions. The results were analyzed using an
ABI Prism 3130XL Applied Biosystems DNA sequencer.
Methylation-Sensitive Restriction Enzyme PCR
CpG methylated WGA DNA, unmethylated WGA DNA or
cell line DNA was digested with HpyCH4IV, following
manufacturer's instructions. PCR was carried out in a 25
μl volume containing 25 ng of digested DNA (or undi-
gested DNA as control), 1 μl of each primer pair (2 mM
stock) for either MMP-1 or MMP-3, 2 μl of 2.5 mM dNTP
mix (Invitrogen), 2.5 μl of 10x PCR buffer, 1.25 μl of 50
mM MgCl2, 0.1 μl of Platinum Taq DNA polymerase (5 U/
μl) (Invitrogen) and sterile H2O up to a final volume of 25
μl.
Amplification was performed as described above and 5 μl
of each amplification reaction was electrophoresed
through a 1% agarose gel and stained with ethidium bro-
mide in order to analyse results.
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